Divi’s Laboratories gains over 3% as Citi reiterates buy, calls stock a ‘top pick’

Divi’s Laboratories shares gained over 3 per cent as analysts flagged 2026 as a potential inflection point, driven by a ...

Divi's Labs, Lupin, other pharma stocks rise up to 4%; here's why HDFC Securities says sector looks 'attractive'

India's share in global CRDMO market will likely rise to 4.7% by 2029 from 3.8% in 2024, making it an attractive sector, HDFC ...
CNBCTV18

2026 an 'inflection year' for Divi's Laboratories; Citi sees 43% upside

Citi said it believes Divi's Laboratories' revenue and earnings before interest, tax, depreciation, and amortisation (EBITDA) ...
Indiatimes

How 12th fail teen turned Hyderabad’s richest businessman

Dr Murali Krishna Prasad Divi's resilience and strategic decisions have propelled Divi’s Labs to global success as a top API manufacturer. The company's commitment to chemistry and customer ...
Seeking Alpha

DIVI: The Rare International ETF That Gets It Right

DIVI stands out among international dividend ETFs due to its methodology emphasizing value, earnings stability, and profitability, not just high yield. The ETF's optimization process allows for growth ...